Chondroitin sulphate for symptomatic osteoarthritis: Critical appraisal of meta-analyses

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1303-1308

  Monfort, Jordi ^a   Martel Pelletier, Johanne ^b   Pelletier, Jean Pierre ^b,c  

^a Barcelona Biomedical Research Park   (Spain)

^b NOTRE DAME HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Chondroitin sulphates, diagnostic use; Glycosaminoglycans; Osteoarthritis, drug therapy; Osteoarthritis, knee

Indexed keywords

CHONDROITIN SULFATE; GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO;

ANALGESIA; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFORMATION RETRIEVAL; MEDLINE; OSTEOARTHRITIS; UNSPECIFIED SIDE EFFECT;

EID: 44349163409     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X297231     Document Type: Article

References (42)

1. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997; 350:503-8
2. MacLean CH, Knight K, Paulus H, et al. Costs attributable to osteoarthritis. J Rheumatol 1998;25:2213-8
3. Lawrence RC, Heimick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
4. Morreale P, Manopulo R, Galati M, et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23:1385-91
5. du Souich P, Verges J. Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clin Pharmacol Ther 2001; 70:5-9
6. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55
7. Zhang W, Moskowitz RW. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence activity. Osteoarthritis Cartilage 2007;15:981-9
8. Fajardo M, Di Cesare PE. Disease-modifying therapies for osteoarthritis: current status. Drugs Aging 2005;22:141-61
9. Hardingham T. Chondroitin sulfate and joint disease. Osteoarthritis Cartilage 1998;6(Suppl A):3-5
10. Volpi N. The pathobiology of osteoarthritis and the rationale for using chondroitin sulfate for its treatment. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:119-27
11. Bali JP, Cousse H, Neuzil E. Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system. Semin Arthritis Rheum 2001;31:58-68
12. Monfort J, Pelletier J-P, Garcia-Giralt N, Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulfate on osteoarthritis articular tissues. Ann Rheum Dis 2007;doi:10.1136/ard.2006.068882
13. Simanek V, Kren V, Ulrichova J, Gallo J. The efficacy of glucosamine and chondroitin sulfate in the treatment of osteoarthritis: are these saccharides drugs or nutraceuticals? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005,149:51-6
14. Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998;6(Suppl A):39-46
15. Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004;12:269-76
16. Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779-86
17. Kahan A, Reginster J-Y, Vignon E. STOPP (STudy on Osteoarthritis Progression Prevention): a new two-year trial with chondroitin 4 & 6 sulfate (CS). Accessed at URL: http://www.ibsa-ch.com/eular_2006_amsterdam_vignon-2. pdf, date September 20, 2006
18. Gross JI, Mathews MB, Dorfman A. Sodium chondroitin sulfate-protein complexes of cartilage. II. Metabolism. J Biol Chem 1960;235:2889-92
19. Hutterer F. Degradation of mucopolysaccharides by hepatic lysosomes. Biochim Biophys Acta 1966;115:312-9
20. Andermann G, Dietz M. The influence of the route of administration on the bioavailability of an endogenous macromolecule: chondroitin sulphate (CSA). Eur J Drug Metab Pharmacokinet 1982;7:11-6
21. Konador A, Kawiak J. Changes in chondroitin sulfate concentration in rabbit blood plasma depending on the method of its administration. Arch Immunol Ther Exp (Warsz) 1977;25:895-903
22. Wood KM, Wusteman FS, Curtis CG. The metabolic fate of chondroitin (35S) sulphate proteoglycan in the rat. Biochem Soc Trans 1975;3:500-2
23. Konador A, Kawiak J. Distribution of radioactivity in the mouse organism after administration of 35S-chondroitin sulphate. Folia Biol (Krakow) 1976;24:177-90
24. Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11
25. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. J Am Med Assoc 2000;283:1469-75
26. Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163:1514-22
27. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007;146:580-90
28. Bjordal JM, Klovning A, Ljunggren AE, Slørdal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007;11:125-38
29. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New Engl J Med 2006;354:795-808
30. Helg AG, de Vathaire F. How solid are the results of the meta-analysis by Reichenbach et al. and its conclusions? [Letter]. http://www.annals.org/cgi/ eletters/146/8/580#15862, accessed at URL, date 30 November 2007
31. Pelletier JP. Chondroitin sulfate meta-analysis: the jury is not yet out. [Letter]. http://www.annals.org/cgi/eletters/146/8/580#15862, accessed at URL, date 16 May 2007
32. Goldberg HA, Avins AL. Interpretation of chondroitin meta-analysis. [Letter].: http://www.annals.org/cgi/eletters/146/8/580#15862, accessed at URL, date 23 April 2007
33. du Souich P. Clinical usefulness of chondroitin sulphate. [Letter]. http://www.annals.org/cgi/eletters/146/8/580#15862, accessed at URL, date 19 April 2007
34. Bourgeois P, Chales G, Dehais J, et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400mg/day vs placebo. Osteoarthritis Cartilage 1998;6(Suppl A):25-30
35. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998;6(Suppl A):39-46
36. Pavelka K, Manopulo R, Busci L. Double-blind, dose-effect study of oral chondroitin 4 & 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rheumatologica 1999;24:21-30
37. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New Engl J Med 2006;354:795-808
38. Omata T, Itokazu Y, Inoue N, Segawa Y. Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. Arzneimittelforschung 2000;50:148-53
39. Mazières N, Hucher M, Zaïm M, Garnero P. Effect of chondroitin sulfate in symptomatic knee osteoarthritis: a multicenter, randomized, double blind, placebo-controlled study. Ann Rheum Dis 2007;66:639-45
40. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389-99
41. Hathcock JN, Shao A. Risk assessment for glucosamine and chondroitin sulfate. Regul Toxicol Pharmacol 2007;47:78-83
42. Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007;24:573-80